A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The UK company buys IRDx for $1bn.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
